Clinical trials
Liver Transplant Rejection clinical trials
Below are recruiting liver transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT05655273Enrolling by invitationPhase 4
Switch tacrolimus timing after liver transplant to Envarsus
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
Toronto, OntarioAges 18–99 - NCT06734013Recruiting
Genetic testing to help diagnose liver transplant rejection
This study looks at whether genetic testing of a tissue sample (biopsy) can help doctors more accurately diagnose rejection after a liver transplant. It is for people who have already been diagnosed with rejection and have a stored tissue sample available.
BolognaAges 18 years+ - NCT06717542Recruiting
Liver tissue analysis to predict transplant success
This study looks at liver tissue before transplantation to find ways to predict how well the transplant will work. It involves a special treatment called HOPE to help preserve the liver.
BolognaAges 18 years+ - NCT07735650Enrolling by invitation
Safe withdrawal of immune meds after liver transplant
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
TaoyuanAges 20 years+ - NCT05793203Recruiting
Tests noninvasive checks to spot liver transplant complications early
This study looks at how well noninvasive tests (tests that don’t require surgery or taking tissue) can detect complications after a liver transplant. It may help patients and teams find problems earlier using safer, easier monitoring.
RomeAges 18–75 - NCT06400771RecruitingPhase 1
Safety of DNP007 in Healthy Volunteers
This study tests the safety of a new drug called DNP007 in healthy volunteers. It is a Phase 1 trial, meaning it's one of the first steps in humans to see if the drug is safe and how the body handles it.
SeoulAges 19–55 - NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85 - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT05285878Enrolling by invitationPhase 2
Fingolimod to protect kidney function after kidney transplant
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Houston, TexasAges 18–65 - NCT05082077Enrolling by invitation
Liver transplant donor data registry for better organ preservation
This study builds a global registry that tracks how donor livers are matched and preserved for transplant. It may help improve how doctors keep donor livers viable before surgery by learning from real-world cases.
Birmingham, AlabamaAges 18 years+ - NCT04234139Enrolling by invitation
Study of severe alcoholic hepatitis patients before early liver transplant
This study follows people with severe alcoholic hepatitis who are being considered for an early liver transplant before they’ve been sober for 6 months. It aims to better understand this group’s situation and ethics/safety as early transplantation plans are made.
Baltimore, MarylandAges 18 years+ - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
San Francisco, CaliforniaAges 18 years+ - NCT07530913Enrolling by invitation
Digital Rehabilitation Platform for Liver Transplant Patients
This study tests a smartphone or tablet-based exercise program designed to help people recovering from living donor liver transplant surgery. The goal is to see if using guided exercises on a digital device at home improves recovery and quality of life after transplant.
SeoulAges 20–65 - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT04838171Recruiting
Study of White Blood Cells in Donors and Patients
This study looks at white blood cells (the body’s immune cells) to learn more about how they behave in health and/or illness. Participation may help researchers understand immune-related changes and support future treatments.
LondonAges Any age - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Phoenix, ArizonaAges 18 years+ - NCT07053462RecruitingPhase 1/Phase 2
Gene-edited kidney transplant to lower rejection risk
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Beijing, ChangpingAges 16–85 - NCT04204850RecruitingPhase 2
Cabozantinib for liver cancer that returns after liver transplant
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Toronto, OntarioAges 18 years+ - NCT01757730Recruiting
MRI test to measure soft tissue stiffness
This trial uses a special type of MRI to estimate how stiff certain soft tissues are in the body. You may benefit by helping doctors better measure tissue stiffness, which can relate to different health problems.
Columbus, OhioAges 18 years+ - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT07046910RecruitingPhase 2
MRI to detect lung rejection after transplant
This study uses a special MRI scan (called hyperpolarized gas MRI) to check for signs of lung rejection after a transplant. The goal is to see if the MRI can help detect rejection earlier and more safely than standard bronchoscopy alone.
Charlottesville, VirginiaAges 18–80 - NCT05744635Recruiting
Study tacrolimus levels after liver transplant
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
BudapestAges 18 years+
Hear when a new Liver Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver transplant rejection?
- Yes. Clin2 currently lists 38 recruiting liver transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.